FDA Is Using Agentic AI to Support Inspections: Is This a Game Changer for QA?
What changes for inspection readiness when FDA can cross-check faster—and what QA should do now.
Who This Is For
- QA leaders and site quality teams preparing for FDA inspections
- Quality system owners accountable for deviations/CAPA, change control, training, and trending
- Submission support teams who must align the “quality story” with operational reality
Introduction
FDA has announced an agency-wide deployment of agentic AI capabilities for internal use—specifically to enable “more complex AI workflows… to assist with multi-step tasks,” including “inspections and compliance.” [1]
This does not change predicate rules by itself. But it can change the inspection experience: when review and inspection workflows are faster and more cross-referential, gaps in execution, weak linkage, and internal inconsistency surface sooner. For additional context on how FDA frames AI within quality expectations, see FDA’s current position on AI in pharmaceutical quality systems.
Hard line (process-accurate): SOPs define expectations. Objective evidence proves execution—and inspection-speed evidence is how you demonstrate control.
In other words: this is not a debate about tools. It is a stress test of your ability to demonstrate control over processes, records, and Data Integrity—quickly, coherently, and without contradictions. If you need help strengthening this capability across regulated operations, see Data Integrity program development and risk-based remediation.
Key Takeaways
- Agentic AI matters because it supports multi-step workflows (find → compare → reconcile → draft targeted questions).
- In faster oversight environments, contradictions become a primary risk driver.
- QA advantage shifts toward evidence orchestration: coherent narratives + rapid retrieval + consistency across SMEs.
- “Do you follow your own SOPs?” is not a soft question—it’s a common basis for inspection observations and warning letters.
What This Is NOT
- Not a new predicate rule. FDA modernization doesn’t change your obligations; it changes how efficiently adherence can be evaluated.
- Not “AI replacing investigators.” FDA describes built-in guidelines and human oversight; the tool is optional for staff. [1]
- Not a reason to reinvent the wheel. The win is stronger execution, stronger linkage, and faster demonstrability of the QMS you already operate.
If you want a broader (still risk-based) view of operational considerations for AI/ML in regulated settings, see risk-based planning for AI/ML in regulated environments.
What Agentic AI Means—and Why It Enhances Inspection Capability
Most people think of Artificial Intelligence as “answering one question” or “summarizing one document.” FDA’s description of agentic AI points to goal-driven, multi-step work—systems designed to complete tasks under built-in guidelines and human oversight. [1]
In inspection terms, multi-step workflows can translate into practical acceleration:
- Faster focusing: helping inspectors zero in on records and process steps that matter most—especially where the evidence trail looks incomplete, inconsistent, or difficult to reconcile.
- Faster cross-referencing: comparing SOP expectations vs execution across deviations/CAPA, training, change control, and trending.
- More precise questions: “show me” probes that are tightly tied to a specific gap in the evidence trail.
What changes for QA is not the expectation—it’s the speed and coherence with which adherence can be evaluated.
Run the QMS vs Prove the QMS
When inspections become more cross-referential, QA needs two muscles: running the QMS consistently, and proving the QMS quickly with objective evidence. Agentic AI support increases the likelihood FDA can test both efficiently. [1]
Run the QMS
Operational compliance: the system works as written.
- SOPs are followed consistently (and exceptions are controlled)
- Deviations/CAPA logic matches effectiveness checks
- Training aligns to task performance
- Change control matches real operational changes
QA question: Are we running the process we claim we run?
Prove the QMS
Inspection performance: the system can be demonstrated quickly and coherently.
- Evidence is retrievable rapidly (without scramble mode)
- Answers are consistent across SMEs and functions
- Timelines reconcile across records
- Decision trails are complete (what/why/who/when)
QA question: Can we demonstrate control at inspection speed—without contradictions?
What Changes in Inspections When Oversight Gets Faster
1) Inspections become more cross-referential
Expect more cross-checking between:
- SOPs ↔ executed records
- Deviations ↔ CAPA ↔ effectiveness ↔ trending
- Training ↔ role performance ↔ approvals
- Change control ↔ effective dates ↔ operational reality
Result: contradictions become a primary risk driver.
2) Questions get sharper and closer to objective evidence
Expect fewer broad narratives and more evidence-anchored requests:
- “Show proof this SOP step was executed for the last X events.”
- “Show where the decision was made and who approved it.”
- “Show the documented timeline that supports the conclusion.”
- “Show how you verified effectiveness using your acceptance criteria.”
3) “Are you following your own SOPs?” is evaluated more efficiently—and cited often
When SOP steps, training records, and execution evidence don’t reconcile, the gap becomes visible quickly—especially during cross-checking inspections.
Lead-in: If you want one “always relevant” inspection theme, it’s this: procedures only matter if execution matches them.
This is already a classic inspection theme, and it’s frequently visible in public enforcement artifacts.
Examples in FDA public enforcement records include:
- A Form FDA 483 for Samsung Biologics Co., Ltd. includes an observation stating that procedures were not followed and references nonconformance to an SOP in practice. [2]
- A warning letter to Global Pharma Healthcare Private Limited explicitly states: “You failed to follow your change management procedure ….” [5]
- A warning letter to Catalent Indiana, LLC cites failure to “establish and follow appropriate written procedures” designed to prevent microbiological contamination, referencing 21 CFR 211.113(b). [3] [4]
In a workflow-accelerated oversight environment, these “follow your own procedure” gaps can surface faster because they create patterns: missing steps, late approvals, inconsistent decision criteria, and timelines that don’t reconcile.
What QA Should Do Differently Now
1) Make predicate-rule adherence demonstrable at inspection speed
Use an inspection-speed evidence pack to connect SOP expectations to objective records, decision trails, and CAPA linkages in one coherent view.
For each critical process, define “inspection-speed evidence”:
- Required steps and approvals
- Decision points and escalation triggers
- Required records and where they live
- Who owns retrieval and who verifies completeness
Internal test: If FDA asked for proof this SOP was executed over the last 90 days, can we produce it in one hour—complete, consistent, and reconcilable?
Note (light-touch, not a validation pivot): In CSV / Computer System Validation terms, this is simply a disciplined way to keep procedures, records, and system outputs aligned so the evidence is inspection-ready without “scramble mode.” If you need support in this area, see CSV / Computer System Validation support for regulated systems.
2) Reduce internal inconsistencies across the quality system
Reducing internal inconsistencies starts with cross-functional alignment—so SOP expectations, records, CAPA, training, and change control tell the same story.
Lead-in: Most inspection pain is “say/do” misalignment—where the system narrative and the record reality don’t match.
- SOP says A, records show B
- CAPA effectiveness checks don’t test the root cause
- Training assignments don’t match who performed the task
- Change control dates don’t match when practice changed
Practical habit: run a monthly Say/Do Alignment Review (one process at a time): SOP → sample executions → outcomes → trends.
3) Harden what’s most “machine-checkable”
These controls fail loudly under cross-reference:
- Completeness (no missing steps/approvals)
- Consistency (the same fact is the same everywhere)
- Timeliness (timelines are followed or justified)
- Traceability (cause → action → outcome is linkable)
- Repeatability (each execution produces the expected evidence set)
Translate this into minimum evidence sets for your highest-risk processes—then test retrieval under realistic inspection conditions.
FAQ
Does FDA’s agentic AI deployment create new compliance requirements for industry?
Not by itself. Predicate rules and existing quality system expectations still apply. What changes is the likelihood that expectations can be evaluated more efficiently, increasing the practical importance of coherence, traceability, and demonstrable SOP adherence. [1]
What does “inspection-speed evidence” mean in practice?
It means you can produce a complete, reconcilable package quickly: the SOP expectation, objective evidence of execution, the decision trail (who/what/when/why), and any follow-up actions (e.g., deviation/CAPA and effectiveness).
Why is “following your own SOPs” still such a dominant inspection theme?
Because documented procedures are only meaningful if execution matches them. FDA frequently cites failures to follow established procedures in Form 483s and warning letters. [2] [3] [5]
Where should QA prioritize effort first?
Start where cross-referencing creates the most exposure: deviations/CAPA linkages, training-to-task alignment, change control effectiveness, and trending that matches what the records actually show.
Conclusion
FDA’s agentic AI deployment is an explicit signal: the agency is investing in multi-step workflow support that includes inspections and compliance. [1]
For QA, the practical response is to build two muscles:
- Run the QMS: consistent execution against defined procedures
- Prove the QMS: objective evidence, coherent timelines, and consistent answers at inspection speed
In a faster cross-referential oversight environment, contradictions become a primary risk driver—because inconsistencies are more efficiently detected and harder to defend. This is why “follow your own SOPs” remains one of the most durable inspection themes, visible across 483s and warning letters. [2] [3] [5]
About Xevalics Consulting
Xevalics Consulting, LLC supports regulated organizations in the responsible design, qualification, and governance of agent-enabled technologies within controlled digital environments.
Our focus is the qualified, controlled, and auditable deployment of modern technologies to support regulated processes without compromising scientific integrity or regulatory expectations.
Transparency Statement
This article was developed with the assistance of artificial intelligence tools to support research synthesis, drafting, and editorial refinement. Human subject-matter expertise guided all analytical decisions. Xevalics Consulting, LLC retains full responsibility for the content and perspectives expressed.
Regulatory and Compliance Disclaimer
This article is provided for informational and educational purposes only and does not constitute regulatory guidance, legal advice, or an official interpretation of applicable laws, regulations, or guidance documents. Organizations remain solely responsible for determining regulatory applicability and compliance.
Works Cited
- FDA. “FDA Expands Artificial Intelligence Capabilities with Agentic AI Deployment.” (Dec 1, 2025). https://www.fda.gov/news-events/press-announcements/fda-expands-artificial-intelligence-capabilities-agentic-ai-deployment
- FDA. Form FDA 483 — Samsung Biologics Co., Ltd. (May 2025). https://www.fda.gov/media/189387/download
- FDA. Warning Letter — Catalent Indiana, LLC (Nov 20, 2025). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/catalent-indiana-llc-718189-11202025
- eCFR. 21 CFR 211.113(b). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-F/section-211.113
- FDA. Warning Letter — Global Pharma Healthcare Private Limited (Oct 20, 2023). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/global-pharma-healthcare-private-limited-657325-10202023
